• Register
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.


Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.


Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.

Studies on postmortem brains from Parkinson's patients reveal elevated iron in the substantia nigra (SN). Selective cell death in this brain region is associated with oxidative stress, which may be exacerbated by the presence of excess iron. Whether iron plays a causative role in cell death, however, is controversial. Here, we explore the effects of iron chelation via either transgenic expression of the iron binding protein ferritin or oral administration of the bioavailable metal chelator clioquinol (CQ) on susceptibility to the Parkinson's-inducing agent 1-methyl-4-phenyl-1,2,3,6-tetrapyridine (MPTP). Reduction in reactive iron by either genetic or pharmacological means was found to be well tolerated in animals in our studies and to result in protection against the toxin, suggesting that iron chelation may be an effective therapy for prevention and treatment of the disease.

Pubmed ID: 12670420


  • Kaur D
  • Yantiri F
  • Rajagopalan S
  • Kumar J
  • Mo JQ
  • Boonplueang R
  • Viswanath V
  • Jacobs R
  • Yang L
  • Beal MF
  • DiMonte D
  • Volitaskis I
  • Ellerby L
  • Cherny RA
  • Bush AI
  • Andersen JK



Publication Data

March 27, 2003

Associated Grants

  • Agency: NIA NIH HHS, Id: 2R01AG12686
  • Agency: NIA NIH HHS, Id: R01 AG12141
  • Agency: NIA NIH HHS, Id: R01 AG41264

Mesh Terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • 3,4-Dihydroxyphenylacetic Acid
  • Animals
  • Blotting, Western
  • Cell Death
  • Clioquinol
  • Dopamine
  • Ferritins
  • Gene Expression
  • Genetic Therapy
  • Homovanillic Acid
  • Humans
  • Immunohistochemistry
  • Iron
  • Iron Chelating Agents
  • Mice
  • Mice, Transgenic
  • Oxidative Stress
  • Parkinson Disease
  • Parkinson Disease, Secondary
  • Promoter Regions, Genetic
  • Rats
  • Substantia Nigra
  • Tyrosine 3-Monooxygenase